Sep 10, 2019 / 01:10PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director
Matthew Harrison, one of the biotech analysts here.
Before we get started, I just need to read the disclosure statement. Please note that all important disclosures, including personal holdings disclosures and Morgan Stanley disclosures, appear on the Morgan Stanley public website at morganstanley.com/researchdisclosures or you can pick up your very own copy at the registration desk. So very pleased to have Amgen for our next session. Bob Bradley, who's the CEO; and David Meline, the CFO, up here on stage. Bob, I know you want to probably make some opening comments, and then we can jump into it.
Robert A. Bradway - Amgen Inc. - Chairman, CEO & President
Thank you, Matthew. Well, let me start by thanking you and your colleagues for hosting this event. Appreciate you having us here and appreciate all of you being with us in the room this morning.
I think as you saw, Matthew, through the report of the first 2 quarters, we're executing well into 2019. For us,
Amgen Inc at Morgan Stanley Healthcare Conference Transcript
Sep 10, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers